University of California, San Francisco
Carboxymethyldextran-A2-Gd-DOTA not suitable for use as MRI contrast agent
Published in Medical Imaging Week, December 31st, 2005
In a study from the United States, "carboxymethyldextran (CMD)-A2-Gd-DOTA, a slow clearance blood pool contrast agent with a molecular weight of 52.1 kDa, designed to have intravascular residence for more than 1 h, was evaluated for its potential to characterize and differentiate the microvessels" of malignant and benign tumors.
"Precontrast single-slice inversion-recovery snapshot FLASH and dynamic contrast-enhanced MRI using an axial T1-weighted 3-dimensional spoiled gradient recalled sequence was performed in 30...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Imaging Week
Source: Medical Imaging Week (2005-12-31)
More Articles from Medical Imaging Week
- Federal University of Sao Paulo
Administration of dexrazoxane during treatment with doxorubicin resulted in less cardiotoxicity - InSightec, Ltd.
Alliance to study use of magnetic resonance focused ultrasound to eliminate breast tumors - Schering AG
Alliance formed to develop medical equipment and contrast agents for optical imaging - University of Pennsylvania
ATP citrate lyase inhibition suppressed tumor cell growth - Acacia Research Corp.
Rights acquired to patents for archiving and transmitting medical images - Adelaide & Meath Hospital, Dublin
Virtual laryngoscopy recommended for patients who cannot tolerate clinical examination - More from this issue of Medical Imaging Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
